Togaviridae Or Flaviviridae, Except Hepatitis C Virus (e.g., Yellow Fever Virus, Bovine Viral Diarrhea Virus, Dengue Virus, Equine Viral Arteritis Virus, Equine Encephalitis Virus, Japanese B Encephalitis Virus, Sindbis Virus, Flavivirus, Etc.) Patents (Class 424/218.1)
-
Patent number: 12194086Abstract: Disclosed herein is a composition comprising a nucleic acid sequence encoding a Mayaro Virus antigen that elicits an immune response in a mammal. Also disclosed herein is a nucleic acid sequence encoding an anti-Mayaro Virus antibody, a fragment thereof, a variant thereof. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Mayaro virus infection in a subject using said composition and method of generation.Type: GrantFiled: October 12, 2018Date of Patent: January 14, 2025Assignee: The Wistar Institute of Anatomy and BiologyInventors: David B. Weiner, Kar Muthumani, Sagar Kudchodkar
-
Patent number: 11896636Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.Type: GrantFiled: July 6, 2012Date of Patent: February 13, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Ethan Settembre
-
Patent number: 11730801Abstract: The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3? untranslated region (3?UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.Type: GrantFiled: February 14, 2018Date of Patent: August 22, 2023Assignee: Board of Regents, The University of Texas SystemInventors: Pei-Yong Shi, Xuping Xie, Chao Shan
-
Patent number: 11578103Abstract: Transcriptional units encoding Zika virus (ZIKV) premembrane (prM) and envelope (E) proteins, which upon translation form Zika virus-like particles (VLPs), are described. Use of the transcriptional units and VLPs in three different ZIKV vaccine platforms is described. Immunoassay-based detection methods using ZIKV VLPs are described for the diagnosis of ZIKV infection.Type: GrantFiled: February 5, 2021Date of Patent: February 14, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gwong-Jen J. Chang, Brent S. Davis
-
Patent number: 11484567Abstract: The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.Type: GrantFiled: April 10, 2014Date of Patent: November 1, 2022Assignees: Aarhus Universitet, iSD Immunotech ApSInventors: Shervin Bahrami, Mogens Ryttergård Duch, Christian Kanstrup Holm, Magdalena Janina Laska
-
Patent number: 11464815Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.Type: GrantFiled: March 7, 2019Date of Patent: October 11, 2022Assignee: Takeda Vaccines, Inc.Inventor: Derek Wallace
-
Patent number: 11406698Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.Type: GrantFiled: March 8, 2020Date of Patent: August 9, 2022Assignee: Bharat Biotech International LimitedInventors: Kandaswamy Sumathy, Krishna Murthy Ella
-
Patent number: 11406700Abstract: Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.Type: GrantFiled: April 6, 2020Date of Patent: August 9, 2022Assignee: Valneva SEInventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schiegl, Michael Weber, Jürgen Heindl-Wruss
-
Patent number: 11351247Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.Type: GrantFiled: August 30, 2018Date of Patent: June 7, 2022Assignee: INPROTHER APSInventors: Peter Holst, Christian Thirion, Lasse Neukirch
-
Patent number: 11285202Abstract: A polymer-protein core-shell nanoparticle is generally provided. In one embodiment, the polymer-protein core-shell nanoparticle includes a pyridinyl group grafted polymer assembled with a protein or a glycoprotein based antigen to form a core-shell particle. A method is also generally provided for treating an infected organism. In one embodiment, the method includes administering the polymer-protein core-shell nanoparticle to the infected organism.Type: GrantFiled: January 26, 2017Date of Patent: March 29, 2022Assignee: University of South CarolinaInventors: Qian Wang, L. Andrew Lee
-
Patent number: 11235051Abstract: Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.Type: GrantFiled: July 27, 2018Date of Patent: February 1, 2022Assignees: Janssen Vaccines & Prevention B.V., Massachusetts Institute of TechnologyInventors: Ronald Vogels, Marijn Van Der Neut Kolfschoten, Darrell J. Irvine, Ron Weiss, Ely Blanton Porter, Mariane Bandeira Melo, Tasuku Kitada
-
Patent number: 11207397Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.Type: GrantFiled: December 4, 2019Date of Patent: December 28, 2021Assignee: Valneva SEInventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schiegl, Michael Weber, Jürgen Heindl-Wruss
-
Patent number: 11083786Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: GrantFiled: January 18, 2019Date of Patent: August 10, 2021Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason DeHart
-
Patent number: 10913716Abstract: The present invention concerns substituted indoline compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: March 31, 2017Date of Patent: February 9, 2021Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Jean-François Bonfanti, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
-
Patent number: 10881723Abstract: The present invention relates to a vaccine containing fixed virus particles, wherein a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles.Type: GrantFiled: January 10, 2017Date of Patent: January 5, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Hiroto Onuma, Yukari Tsurudome, Kazuyuki Ikeda, Ryo Yamaue, Kazuhiko Kimachi, Motoharu Abe, Akihiro Watanabe, Yuki Ohara
-
Patent number: 10869920Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.Type: GrantFiled: October 8, 2019Date of Patent: December 22, 2020Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Government of the United States, as represented by The Secretary of The ArmyInventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
-
Patent number: 10588956Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.Type: GrantFiled: July 18, 2016Date of Patent: March 17, 2020Assignee: Bharat Biotech International LimitedInventors: Kandaswamy Sumathy, Krishna Murthy Ella
-
Patent number: 10533997Abstract: Embodiments of the invention are directed to stable full-length cDNA clones of a clinical, Asian lineage ZIKV strain. Certain embodiments of the invention are directed to high-throughput assays for ZIKV and dengue virus (DENV) diagnosis.Type: GrantFiled: May 3, 2017Date of Patent: January 14, 2020Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Pei-Yong Shi, Chao Shan, Xuping Xie
-
Patent number: 10463741Abstract: The present invention provides a composition for use as the protectant for a live attenuated influenza virus vaccine, comprising the following components at the following concentrations: human serum albumin: 1.0-15.0 g/L, sugar: 15.0-95.0 g/L, and sodium glutamate: 0.5-15.0 g/L. The present invention also provides a process for preparing a live attenuated influenza vaccine with the composition according to the present invention, comprising the following steps: dissolving the components of the composition according to the present invention sequentially into a pH buffer solution, adjusting the pH to a specified value, performing filtration sterilization, and adding virus stock to give the live attenuated influenza vaccine. The present invention further provides a live attenuated influenza vaccine, which may be used as an injection or nasal spray.Type: GrantFiled: April 26, 2016Date of Patent: November 5, 2019Assignee: Changchun BCHT Biotechnology Co.Inventors: Zhenwei Shen, Xiaohui Chen, Fei Xu, Yao Sun, Xiaogeng Cheng, Changlin Zhu, Chunlai Jiang, Wei Kong
-
Patent number: 10369209Abstract: A group of mosquito-borne flaviviruses that cause fatal encephalitis in humans is among the most important of all emerging human pathogens of global significance. This group includes Japanese encephalitis virus (JEV), West Nile virus, St. Louis encephalitis virus, and Murray Valley encephalitis virus. In the present disclosure, the first reverse genetics system has been developed for SA14-14-2, a live JE vaccine that is most commonly used in most JE-endemic areas, by constructing an infectious bacterial artificial chromosome that contains the full-length SA14-14-2 cDNA. Using this infectious SA 14-14-2 cDNA, combined with a mouse model for JEV infection, a key viral neurovirulence factor has been discovered that is a conserved single amino acid in the ij hairpin adjacent to the fusion loop of the viral E glycoprotein, which regulates viral infectivity into neurons within the central nervous system.Type: GrantFiled: April 10, 2015Date of Patent: August 6, 2019Assignee: Utah State UniversityInventor: Young-Min Lee
-
Patent number: 10357553Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.Type: GrantFiled: October 26, 2018Date of Patent: July 23, 2019Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.Inventor: Bruce W. Lyday
-
Patent number: 10357558Abstract: The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.Type: GrantFiled: August 1, 2010Date of Patent: July 23, 2019Assignee: Fundacao Oswaldo CruzInventors: Ada Maria de Barcelos Alves, Adriana de Souza Azevedo, Ricardo Galler, Marcos da Silva Freire
-
Patent number: 10351597Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.Type: GrantFiled: May 12, 2015Date of Patent: July 16, 2019Assignee: CAREGEN CO., LTD.Inventors: Yong Ji Chung, Eun Mi Kim
-
Patent number: 10293038Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.Type: GrantFiled: October 26, 2018Date of Patent: May 21, 2019Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.Inventor: Bruce W. Lyday
-
Patent number: 10238734Abstract: The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracelluar signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish.Type: GrantFiled: March 22, 2011Date of Patent: March 26, 2019Assignee: The Regents of the University of CaliforniaInventors: Richard Syd Kornbluth, Geoffrey William Stone
-
Patent number: 10201602Abstract: A live or inactivated recombinant vaccine is described, comprising a viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the viral vector is capable of generating a cell immune response due to an increased alpha and/or gamma interferon production, and is capable of a quick replication, and it has inserted a nucleotide sequence of the ORF 5 and ORF 6 from PRSS.Type: GrantFiled: May 7, 2011Date of Patent: February 12, 2019Assignee: LABORATORIO AVI-MEX, S.A. DE C.V.Inventors: Bernardo Lozano-Dubernard, Ernesto Soto-Priante, David Sarfati-Mizrahi, Jesús Horacio Lara-Puente
-
Patent number: 10159727Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.Type: GrantFiled: October 31, 2017Date of Patent: December 25, 2018Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.Inventor: Bruce W. Lyday
-
Patent number: 10143741Abstract: The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.Type: GrantFiled: April 14, 2014Date of Patent: December 4, 2018Assignee: Sanofi Pasteur SAInventors: Alain Bouckenooghe, Remi Forrat, Denis Crevat
-
Patent number: 10081795Abstract: Methods and compositions concerning mutant flaviviruses with host range mutations. In some embodiments the invention concerns nucleotide sequences that encode mutant flavivirus proteins. Viruses comprising these sequences that display reduced replication in mammalian cells are provided. In further aspects of the invention, flavivirus vaccine compositions are provided. In another embodiment the invention provides methods for vaccination against flavivirus infection.Type: GrantFiled: March 23, 2011Date of Patent: September 25, 2018Assignees: Research Development Foundation, Arbovax, Inc.Inventors: Dennis T. Brown, Raquel Hernandez, Malcolm E. Thomas, Katherine M. Smith
-
Patent number: 10058602Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.Type: GrantFiled: June 16, 2014Date of Patent: August 28, 2018Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, The Walter Reed Army Institute of ResearchInventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
-
Patent number: 10004795Abstract: The present invention refers to a process for preparing an attenuated tetravalent dengue vaccine and its product. The present invention also refers to a process for preparing a tetravalent dengue vaccine for administration to a subject, to a method for inducing an immune response to virus dengue serotype 1, 2, 3 and 4 in a patient and to a tetravalent dengue vaccine kit.Type: GrantFiled: September 8, 2015Date of Patent: June 26, 2018Assignee: Fundacao ButantanInventor: Neuza Maria Frazatti Gallina
-
Patent number: 9993544Abstract: The present invention relates i.a. to a CSFV (classical swine fever virus) comprising a substitution of proline to lysine at amino acid position 44 of the E2 protein and a substitution of threonine to aspartic acid at amino acid position 45 of the E2 protein. Further, the present invention provides an immunogenic composition comprising the CSFV of the present invention and the use of the immunogenic composition for reducing the incidence of or severity in an animal of one or more clinical signs associated with CSF. Moreover, the present invention provides a method of differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.Type: GrantFiled: May 22, 2015Date of Patent: June 12, 2018Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Gregor Meyers, Sabine Wirtz
-
Patent number: 9962435Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.Type: GrantFiled: November 8, 2016Date of Patent: May 8, 2018Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
-
Patent number: 9944902Abstract: The present invention describes an efficient commercial scale production method for the preparation of PRRS virus.Type: GrantFiled: February 14, 2012Date of Patent: April 17, 2018Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Elizabeth Jane Berry, Fuad Tawfiq Haddadin, Ali Khazraeinazmpour, Jeremy Kroll, Sonia Regina Cantisano Malburg, Edgar Arnulfo Sandoval Basurto, Stephen Scheerer
-
Patent number: 9861692Abstract: The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine is a live, attenuated dengue vaccine and the second dengue vaccine is a recombinant dengue subunit vaccine or an inactivated dengue vaccine; wherein the live attenuated dengue vaccine comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric flavivirus. The dengue virus vaccine compositions of the invention may further comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.Type: GrantFiled: June 17, 2014Date of Patent: January 9, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Andrew Bett, Beth-Ann Griswold Coller, Govindarajan Dhanasekaran, Ramesh V. Chintala
-
Patent number: 9827303Abstract: The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt. Preferably the amino acid is glutamate, the polyol is sorbitol and optionally also mannitol and the metal salt is a magnesium salt. The solution is dried by vacuum drying or by lyophilization. The methods are particularly useful for preparing dried formulations of viruses such as poliovirus or respiratory syncytial virus to be used for vaccination. The invention also relates to dried formulations prepared in accordance with the methods of the invention and to their use as medicaments, e.g. as vaccines.Type: GrantFiled: March 5, 2013Date of Patent: November 28, 2017Assignee: De Staat der Nederlanden, vert. door de minister van VWS, Ministerie van Volksgezondheid, Welzijn en SportInventors: Heleen Kraan, Jean-Pierre Amorij
-
Patent number: 9790473Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.Type: GrantFiled: April 23, 2015Date of Patent: October 17, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
-
Patent number: 9730997Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.Type: GrantFiled: August 20, 2014Date of Patent: August 15, 2017Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
-
Patent number: 9719994Abstract: The invention relates to a method of in-vitro detection of an infection with a hepatitis C virus (HCV) in a biological sample, comprising the simultaneous detection of the HCV capsid protein and of an antibody directed against said capsid protein, said method using, for capturing the anti-capsid antibodies, a peptide comprising an antigenic fragment derived from the truncated HCV capsid. The invention also relates to the peptide for capturing the anti-capsid antibodies and the kits comprising it.Type: GrantFiled: December 19, 2012Date of Patent: August 1, 2017Assignee: BIO-RAD INNOVATIONSInventors: Stephane Gadelle, Francois Rieunier
-
Patent number: 9701719Abstract: Novel attenuating deletions of Chikungunya virus E2 polypeptides are provided as are attenuated viruses comprising the deletions. Also provided are immunogenic compositions comprising the attenuated viruses and methods of producing such viruses in cells (such as insect cells). Viruses of the embodiments can be used for immunization of animals to provide protection from the pathogenic effects of Chikungunya virus infection.Type: GrantFiled: September 26, 2013Date of Patent: July 11, 2017Assignee: Research Development FoundationInventors: Dennis T. Brown, Raquel Hernandez
-
Patent number: 9683244Abstract: Embodiments are directed compositions related to Eilat virus and uses thereof.Type: GrantFiled: June 21, 2013Date of Patent: June 20, 2017Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Scott C. Weaver, Farooq Nasar, Rodion V. Gorchakov, Hilda Guzman, Naomi Forrester, Gustavo Palacios, Ian W. Lipkin, Robert B. Tesh
-
Patent number: 9655961Abstract: The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.Type: GrantFiled: September 26, 2013Date of Patent: May 23, 2017Assignees: INSTITUT PASTEUR, THEMIS BIOSCIENCE GMBH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Frederic Tangy, Samantha Brandler, Philippe Despres, Andre Habel
-
Patent number: 9642908Abstract: Disclosed is an in vivo equine disease model and a method of preparing the disease model for equine herpesvirus-1 neurological disease comprising a horse having a low pre-exposure level of herpesvirus-specific CTL precursors wherein the horse is experimentally infected with a neuropathogenic strain of equine herpesvirus or a mutant thereof. Also disclosed is a method of quantifying the risk factors and predicting the development of clinical neurologic signs of equine herpesvirus-1 neurological disease in a horse. Also described in the invention is the determination of the risk of developing the clinical neurologic signs by a mathematical equation. A new live, attenuated vaccine formulation is disclosed that is effective against neurologic disease due to equine herpesvirus-1.Type: GrantFiled: July 29, 2009Date of Patent: May 9, 2017Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: George P. Allen, Glenda Ross
-
Patent number: 9637521Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.Type: GrantFiled: June 28, 2012Date of Patent: May 2, 2017Assignee: Emergex Vaccines Holdings LimitedInventor: Ramila Philip
-
Patent number: 9517259Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.Type: GrantFiled: April 11, 2014Date of Patent: December 13, 2016Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
-
Patent number: 9499588Abstract: This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs for production and delivery.Type: GrantFiled: July 22, 2011Date of Patent: November 22, 2016Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Peter W. Mason, Tomohiro Ishikawa
-
Patent number: 9442114Abstract: The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.Type: GrantFiled: July 18, 2014Date of Patent: September 13, 2016Assignee: INSTITUT PASTEURInventors: Philippe Despres, Anne-Claire Brehin, Valerie Marechal, Pierre Charneau, Philippe Souque
-
Patent number: 9422529Abstract: Embodiments are directed compositions related to Eilat virus and uses thereof. Certain aspects are directed to the detection of non-Eilat entities using a chimeric Eilat alphavirus as a capture agent.Type: GrantFiled: October 28, 2014Date of Patent: August 23, 2016Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Farooq Nasar, Jesse Erasmus, Scott C. Weaver
-
Patent number: RE46631Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: May 17, 2013Date of Patent: December 12, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai
-
Patent number: RE46641Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: May 17, 2013Date of Patent: December 19, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai